Johnson & Johnson has increased its quarterly dividend to $1.34 per share, marking the 64th consecutive year of payout growth. For conservative income investors, the raise signals that management remains confident in cash flow despite ongoing legal and competitive pressures.
The latest dividend details
The new quarterly dividend of $1.34 per share is payable June 9, 2026, for shareholders of record May 26, 2026. The annualized rate now stands at $5.36 per share, which produces a yield of approximately 2.3 percent at current prices.
This increase follows a pattern of modest but consistent raises. JNJ has not cut its dividend since at least 1962, making it one of the most reliable income stocks in the healthcare sector.
| Metric | Value |
|---|---|
| Quarterly dividend | $1.34 |
| Annualized dividend | $5.36 |
| Current yield | ~2.3% |
| Payout ratio | ~59% |
| Consecutive years of increase | 64 |
| Ex-dividend date | May 26, 2026 |
| Payment date | June 9, 2026 |
Payout coverage and cash flow signals
The payout ratio of roughly 59 percent suggests that JNJ is retaining about 41 cents of every dollar earned for reinvestment, debt reduction, or acquisitions. That is a comfortable margin for a company of this size.
Revenue in the pharmaceutical segment has remained strong driven by Darzalex, Stelara, and recent oncology launches. Consumer health sales have stabilized after the 2023 Kenvue spinoff, which removed a significant portion of the legacy business.
Free cash flow coverage has historically exceeded the dividend requirement by a wide margin. As long as earnings per share continue to grow in the mid-single digits, the payout should remain safe.
Risks that could pressure the dividend
Investors should watch two potential risks. First, talc litigation exposure remains a headline concern, though the company has moved toward settlement structures that cap cash outflows.
Second, biosimilar competition has begun to erode pricing power on older blockbuster drugs. The company must replace lost revenue with new-product growth to maintain dividend coverage.
Neither risk appears imminent enough to threaten the dividend in the next 12 to 24 months, but both are worth monitoring in quarterly earnings reports.
How JNJ compares to other healthcare dividends
Among large-cap healthcare names, JNJ offers a lower yield than Merck, AbbVie, or Bristol Myers Squibb, but it also carries a stronger balance sheet and a longer track record of increases.
For a retiree building a core income portfolio, JNJ acts more like a treasury bond substitute with growth potential than a high-yield play. The 2.3 percent yield is modest, but the 64-year streak provides peace of mind.
What the ex-dividend date means for new buyers
The May 26, 2026 ex-dividend date is the last day an investor can purchase shares and still receive the June 9 dividend. Buyers after that date will not receive the upcoming payout, though they will still be entitled to future quarterly distributions.
For income-focused investors, timing purchases around ex-dividend dates can matter if you are trying to capture immediate income. However, stock prices typically adjust downward by the dividend amount on the ex-date, so there is no free lunch.
A long-term holder should focus less on a single payment and more on the annual growth rate and payout sustainability over five to ten years.
How to add JNJ to a dividend portfolio
Johnson & Johnson fits best as a core holding in a diversified retirement account. A 5 to 8 percent allocation within the healthcare sleeve of a dividend portfolio is a reasonable framework for a conservative investor.
Investors can buy shares directly through a brokerage account, or they can gain exposure through a dividend-focused ETF that includes JNJ as a top holding. Either approach provides qualified dividend income that is taxed at favorable rates.
The key with JNJ is patience. The stock rarely delivers large capital gains, but the dividend growth and low volatility have made it a staple of retirement portfolios for decades.
Stay ahead with our weekly newsletter
Get stock picks, market analysis, and strategy updates delivered to your inbox every week. Subscribe to AlphaBetaStock’s free newsletter for daily market insights.
